Delcath Systems (NASDAQ:DCTH) Cut to Sell at StockNews.com

StockNews.com downgraded shares of Delcath Systems (NASDAQ:DCTH) from a hold rating to a sell rating in a research note published on Monday.

Other equities analysts have also issued research reports about the company. Stephens restated an overweight rating and set a $25.00 price target on shares of Delcath Systems in a research note on Tuesday, August 6th. HC Wainwright restated a buy rating and issued a $22.00 price target on shares of Delcath Systems in a report on Tuesday, August 6th. Finally, Craig Hallum assumed coverage on shares of Delcath Systems in a research report on Friday, June 28th. They issued a buy rating and a $18.00 price target for the company.

Delcath Systems Trading Down 1.5 %

Shares of DCTH opened at $9.81 on Monday. The firm has a market capitalization of $272.58 million, a P/E ratio of -3.70 and a beta of 0.78. Delcath Systems has a 12-month low of $2.25 and a 12-month high of $11.74. The firm has a fifty day moving average price of $8.67 and a 200-day moving average price of $6.85.

Delcath Systems (NASDAQ:DCTH) last posted its quarterly earnings results on Monday, August 5th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.12). The company had revenue of $7.77 million for the quarter, compared to the consensus estimate of $5.00 million. Delcath Systems had a negative net margin of 474.22% and a negative return on equity of 312.48%. During the same period in the prior year, the firm posted ($0.58) EPS. Analysts predict that Delcath Systems will post -1.33 earnings per share for the current year.

Hedge Funds Weigh In On Delcath Systems

A number of large investors have recently added to or reduced their stakes in DCTH. Levin Capital Strategies L.P. grew its position in shares of Delcath Systems by 12.2% in the 1st quarter. Levin Capital Strategies L.P. now owns 54,969 shares of the company’s stock worth $262,000 after buying an additional 5,969 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new stake in Delcath Systems in the second quarter valued at about $370,000. Renaissance Technologies LLC acquired a new stake in Delcath Systems in the second quarter worth about $694,000. Marshall Wace LLP grew its stake in shares of Delcath Systems by 7.0% during the second quarter. Marshall Wace LLP now owns 92,731 shares of the company’s stock worth $776,000 after acquiring an additional 6,066 shares during the last quarter. Finally, ADAR1 Capital Management LLC acquired a new position in shares of Delcath Systems during the fourth quarter valued at about $962,000. 61.12% of the stock is currently owned by institutional investors.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.